Publicacións nas que colabora con Ángela Peñalva Maqueda (32)

2002

  1. Presence of bovine leptin in edible commercial milk and infant formula

    Journal of Endocrinological Investigation, Vol. 25, Núm. 8, pp. 670-674

2001

  1. Effect of acute pharmacological modulation of plasma free fatty acids on GH secretion in acromegalic patients

    Clinical Endocrinology, Vol. 54, Núm. 4, pp. 509-513

  2. Involvement of nitric oxide in the regulation of growth hormone secretion in dogs

    Neuroendocrinology, Vol. 74, Núm. 4, pp. 213-219

  3. Physiology and possible pathology of growth hormone secretagogues

    Journal of Pediatric Endocrinology and Metabolism, Vol. 14, Núm. SUPPL. 5, pp. 1207-1212

1998

  1. Acute changes in free-fatty acids (FFA) do not alter serum leptin levels

    Journal of Endocrinological Investigation, Vol. 21, Núm. 8, pp. 526-530

  2. Effect of acute pharmacological reduction of plasma free fatty acids on growth hormone (GH) releasing hormone-induced GH secretion in obese adults with and without hypopituitarism

    Journal of Clinical Endocrinology and Metabolism, Vol. 83, Núm. 12, pp. 4350-4354

  3. La administracion por via oral de dosis bajas de growth hormone releasing hexapeptide-6-mas piridostigmina es un estimulo adecuado de la secrecion de GH

    Endocrinologia, Vol. 45, Núm. 10, pp. 341-344

1996

  1. Acipimox-mediated plasma free fatty acid depression per se stimulates growth hormone (GH) secretion in normal subjects and potentiates the response to other GH-releasing stimuli

    Journal of Clinical Endocrinology and Metabolism, Vol. 81, Núm. 3, pp. 909-913

  2. Growth hormone releasing hexapeptide-6 (GHRP-6) in test in the diagnosis of GH-deficiency

    Journal of Pediatric Endocrinology and Metabolism

  3. Impaired growth hormone secretion in obese subjects is partially reversed by acipimox-mediated plasma free fatty acid depression

    Journal of Clinical Endocrinology and Metabolism, Vol. 81, Núm. 3, pp. 914-918

1995

  1. Absence of growth hormone (GH) secretion after the administration of either GH-releasing hormone (GHRH), GH-releasing peptide (GHRP-6), or GHRH plus GHRP-6 in children with neonatal pituitary stalk transection

    Journal of Clinical Endocrinology and Metabolism, Vol. 80, Núm. 11, pp. 3180-3184

  2. Effect of combined administration of growth hormone (GH)-releasing hormone, GH-releasing peptide-6, and pyridostigmine in normal and obese subjects

    Metabolism, Vol. 44, Núm. 6, pp. 745-748

  3. Plasma growth hormone response to growth hormone‐releasing hexapeptide (GH‐RP‐6) in children with short stature

    Acta Pædiatrica, Vol. 84, Núm. 8, pp. 904-908

1994

  1. CONTROL PEPTIDERGICO DE LA SECRECION DE HORMONA DE CRECIMIENTO

    Endocrinologia, Vol. 41, Núm. SUPPL. 2, pp. 9-16

1993

  1. Effect of growth hormone (GH)-releasing hormone (GHRH), atropine, pyridostigmine, or hypoglycemia on GHRP-6-induced GH secretion in man

    Journal of Clinical Endocrinology and Metabolism, Vol. 76, Núm. 1, pp. 168-171

  2. Influence of sex, age and adrenergic pathways on the growth hormone response to GHRP-6

    Clinical Endocrinology, Vol. 38, Núm. 1, pp. 87-91

  3. Massive growth hormone (GH) discharge in obese subjects after the combined administration of GH-releasing hormone and GHRP-6: Evidence for a marked somatotroph secretory capability in obesity

    Journal of Clinical Endocrinology and Metabolism, Vol. 76, Núm. 4, pp. 819-823

1990

  1. Dual and selective actions of glucocorticoids upon basal and stimulated growth hormone release in man

    Neuroendocrinology, Vol. 51, Núm. 1, pp. 51-58

  2. Effect of enhancement of endogenous cholinergic tone with pyridostigmine on the dose-response relationships of growth hormone (GH)-releasing hormone-induced GH secretion in normal subjects

    Journal of Clinical Endocrinology and Metabolism, Vol. 70, Núm. 2, pp. 324-327

  3. ROLE OF CHOLINERGIC MUSCARINIC PATHWAYS ON THE FREE FATTY ACID INHIBITION OF GH RESPONSES TO GHRH IN NORMAL MEN

    Clinical Endocrinology, Vol. 33, Núm. 2, pp. 171-176